^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine kinase stimulant

    Related drugs:
    25d
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Terminated, GenVivo, Inc. | Trial completion date: Mar 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Mar 2026; Sponsor strategic business decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    GEN2 • Valcyte (valganciclovir)
    2ms
    A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
    P2, N=45, Recruiting, Candel Therapeutics, Inc. | N=30 --> 45
    Enrollment change
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    3ms
    ADePT: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, Trogenix ltd
    New P1/2 trial
    |
    valacyclovir
    3ms
    A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
    P2, N=30, Recruiting, Candel Therapeutics, Inc.
    New P2 trial
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    4ms
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=124 --> 37
    Enrollment closed • Enrollment change
    |
    GEN2 • Valcyte (valganciclovir)
    9ms
    PrTK03: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (clinicaltrials.gov)
    P3, N=711, Active, not recruiting, Candel Therapeutics, Inc. | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    9ms
    Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=12, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    9ms
    Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Candel Therapeutics, Inc.
    Trial completion date
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    1year
    GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov)
    P1, N=41, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • temozolomide • ProstAtak (aglatimagene besadenovec) • valacyclovir
    1year
    Dynamic tracking of tumor microenvironment modulation using Kaede photoconvertible transgenic mice unveils new biological properties of viral immunotherapy. (PubMed, Cancer Res Commun)
    Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 action that overcome cell exhaustion and decreases immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti-CTLA-4 antibody therapy.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    ProstAtak (aglatimagene besadenovec)
    over1year
    Phase 1 Study of GEN2 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, GenVivo, Inc. | N=91 --> 124
    Enrollment change • Metastases
    |
    GEN2 • Valcyte (valganciclovir)
    over1year
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=61, Completed, GenVivo, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    GEN2